Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines

International Journal of Oncology

Volumn 38, Issue 6, 2011, Pages 1489-1500

  Kawabata, Rumi ^a,b   Oie, Shinji ^b   Takahashi, Masayuki ^a   Kanayama, Hiroomi ^a   Oka, Toshinori ^b   Itoh, Kohji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 Fluorouracil; Anti androgen drug; Insulin like growth factor binding protein 3; Prostate cancer

Indexed keywords

BICALUTAMIDE; FLUOROURACIL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; PROTEIN P70; SOMATOMEDIN BINDING PROTEIN 3;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANDROGEN ANTAGONISTS; ANDROGENS; ANILIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; NITRILES; PROSTATIC NEOPLASMS; RECEPTORS, GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOSYL COMPOUNDS; UP-REGULATION;

EID: 79955845741     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.991     Document Type: Article

References (45)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer: June 17, 2010 (Epub ahead of print).
2. Namiki M, Akaza H, Lee SE, et al: Prostate Cancer Working Group report. Jpn J Clin Oncol 40 (Suppl 1): i70-i75, 2010.
3. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355: 1491-1498, 2000.
4. Schmitt B, Wilt TJ, Schellhammer PF, et al: Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 57: 727-732, 2001.
5. Miyake H, Hara I and Eto H: Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 96: 791-795, 2005. (Pubitemid 41391382)
6. Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H and Ichikawa Y: Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. Int J Urol 14: 264-267, 2007. (Pubitemid 46423250)
7. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004. (Pubitemid 39315317)
8. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004. (Pubitemid 39315318)
9. Agoulnik IU and Weigel NL: Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 99: 362-372, 2006. (Pubitemid 44435554)
10. Zhang L, Johnson M, Le KH, et al: Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res 63: 4552-4560, 2003. (Pubitemid 36951029)
11. Guo Z, Yang X, Sun F, et al: A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69: 2305-2313, 2009.
12. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL and Tindall DJ: Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68: 5469-5477, 2008.
13. Locke JA, Guns ES, Lubik AA, et al: Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68: 6407-6415, 2008.
14. Dillard PR, Lin MF and Khan SA: Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 295: 115-120, 2008.
15. Grossmann ME, Huang H and Tindall DJ: Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93: 1687-1697, 2001. (Pubitemid 33130257)
16. Zhu ML and Kyprianou N: Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 15: 841-849, 2008.
17. Culig Z, Hobisch A, Cronauer MV, et al: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478, 1994.
18. Orio F Jr, Terouanne B, Georget V, et al: Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines. Mol Cell Endocrinol 198: 105-114, 2002. (Pubitemid 36169940)
19. Burfeind P, Chernicky CL, Rininsland F, Ilan J and Ilan J: Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 93: 7263-7268, 1996. (Pubitemid 26243537)
20. Djavan B, Waldert M, Seitz C and Marberger M: Insulin-like growth factors and prostate cancer. World J Urol 19: 225-233, 2001. (Pubitemid 33777060)
21. LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137, 2003. (Pubitemid 36588961)
22. Liu B, Lee HY, Weinzimer SA, et al: Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem 275: 33607-33613, 2000.
23. Zappala G, Elbi C, Edwards J, Gorenstein J, Rechler MM and Bhattacharyya N: Induction of apoptosis in human prostate cancer cells by insulin-like growth factor binding protein-3 does not require binding to retinoid X receptor-alpha. Endocrinology 149: 1802-1812, 2008.
24. Shahjee H, Bhattacharyya N, Zappala G, Wiench M, Prakash S and Rechler MM: An N-terminal fragment of insulin-like growth factor binding protein-3 (IGFBP-3) induces apoptosis in human prostate cancer cells in an IGF-independent manner. Growth Horm IGF Res 18: 188-197, 2008. (Pubitemid 351492127)
25. Bhattacharyya N, Pechhold K, Shahjee H, et al: Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. J Biol Chem 281: 24588-24601, 2006. (Pubitemid 44274233)
26. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC and Rosenfeld RG: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75: 1046-1053, 1992.
27. Yamada PM and Lee KW: Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol 296: C954-C976, 2009.
28. Peehl DM, Krishnan AV and Feldman D: Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 133: S2461-S2469, 2003.
29. Patel BB, Sengupta R, Qazi S, et al: Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 122: 267-273, 2008. (Pubitemid 350234711)
30. Gucev ZS, Oh Y, Kelley KM and Rosenfeld RG: Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 56: 1545-1550, 1996. (Pubitemid 26104017)
31. Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y and Ueno K: A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 44: 1299-1305, 1997. (Pubitemid 27249311)
32. Miyamoto T, Min W and Lillehoj HS: Lymphocyte proliferation response during Eimeria tenella infection assessed by a new, reliable, nonradioactive colorimetric assay. Avian Dis 46: 10-16, 2002. (Pubitemid 34248813)
33. Saotome K, Morita H and Umeda M: Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxicol In Vitro 3: 317-321, 1989. (Pubitemid 20019736)
34. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL and Pollak M: In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61: 6276-6280, 2001.
35. Hakam A, Yeatman TJ, Lu L, et al: Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 30: 1128-1133, 1999. (Pubitemid 29480878)
36. Turner BC, Haffty BG, Narayanan L, et al: Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57: 3079-3083, 1997. (Pubitemid 27351714)
37. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH and Testa JR: AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 61: 589-593, 2001. (Pubitemid 32128619)
38. Grzmil M, Hemmerlein B, Thelen P, Schweyer S and Burfeind P: Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression. J Pathol 202: 50-59, 2004. (Pubitemid 38072845)
39. Ali O, Cohen P and Lee KW: Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res 35: 726-733, 2003. (Pubitemid 38058176)
40. Kanagaraj P, Vijayababu MR, Ravisankar B, Anbalagan J, Aruldhas MM and Arunakaran J: Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells. J Cancer Res Clin Oncol 133: 351-359, 2007. (Pubitemid 46716699)
41. Liu C, Lian F, Smith DE, Russell RM and Wang XD: Lycopene supplementation inhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor-binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res 63: 3138-3144, 2003. (Pubitemid 36735865)
42. Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI and Gupta S: Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB J 19: 2042-2044, 2005. (Pubitemid 41759759)
43. Buckbinder L, Talbott R, Velasco-Miguel S, et al: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649, 1995.
44. Lee KW, Cobb LJ, Paharkova-Vatchkova V, Liu B, Milbrandt J and Cohen P: Contribution of the orphan nuclear receptor Nur77 to the apoptotic action of IGFBP-3. Carcinogenesis 28: 1653-1658, 2007. (Pubitemid 47289026)
45. Lee KW, Ma L, Yan X, Liu B, Zhang XK and Cohen P: Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J Biol Chem 280: 16942-16948, 2005. (Pubitemid 41389154)